Neuropilin-1 exerts co-receptor function for TGF-beta-1 on the membrane of cancer cells and enhances responses to both latent and active TGF-beta

Carcinogenesis

Volumn 32, Issue 4, 2011, Pages 613-621

  Glinka, Yelena ^a   Stoilova, Snejana ^a   Mohammed, Nada ^a   Prud'homme, Gérald J ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; NEUROPILIN 1; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; TRANSFORMING GROWTH FACTOR BETA1; VITRONECTIN RECEPTOR;

ARTICLE; BINDING ASSAY; BREAST CANCER; CANCER CELL; CELL MEMBRANE; COMPLEX FORMATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE RESPONSE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR AFFINITY; RECEPTOR BINDING; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TUMOR IMMUNITY;

CELL LINE, TUMOR; HUMANS; NEOPLASMS; NEUROPILIN-1; PROTEIN-SERINE-THREONINE KINASES; PROTEOGLYCANS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79953702245     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq281     Document Type: Article

References (53)

1. Pellet-Many, C. et al. (2008) Neuropilins: structure, function and role in disease. Biochem. J., 411, 211-226.
2. Uniewicz, K.A. et al. (2008) Neuropilins: a versatile partner of extracellular molecules that regulate development and disease. Front. Biosci., 13, 4339-4360.
3. Romeo, P.H. et al. (2002) Neuropilin-1 in the immune system. Adv. Exp. Med. Biol., 515, 49-54.
4. Bruder, D. et al. (2004) Neuropilin-1: a surface marker of regulatory T cells. Eur. J. Immunol., 34, 623-630.
5. Bielenberg, D.R. et al. (2006) Neuropilins in neoplasms: expression, regulation, and function. Exp. Cell Res., 312, 584-593.
6. Ellis, L.M. (2006) The role of neuropilins in cancer. Mol. Cancer Ther., 5, 1099-1107.
7. Guttmann-Raviv, N. et al. (2006) The neuropilins and their role in tumorigenesis and tumor progression. Cancer Lett., 231, 1-11.
8. Bagri, A. et al. (2009) Neuropilins in tumor biology. Clin. Cancer Res., 15, 1860-1864.
9. Caunt, M. et al. (2008) Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell, 13, 331-342.
10. Kolodkin, A.L. et al. (1997) Neuropilin is a semaphorin III receptor. Cell, 90, 753-762.
11. He, Z. et al. (1997) Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. Cell, 90, 739-751.
12. Soker, S. et al. (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell, 92, 735-745.
13. Fuh, G. et al. (2000) The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J. Biol. Chem., 275, 26690-26695.
14. Wang, L. et al. (2007) Neuropilin-1 modulates p53/caspases axis to promote endothelial cell survival. PLoS One, 2, e1161.
15. Prahst, C. et al. (2008) Neuropilin-1-VEGFR-2 complexing requires the PDZ-binding domain of neuropilin-1. J. Biol. Chem., 283, 25110-25114.
16. Sulpice, E. et al. (2008) Neuropilin-1 and neuropilin-2 act as coreceptors, potentiating proangiogenic activity. Blood, 111, 2036-2045.
17. Matsushita, A. et al. (2007) Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1. Cancer Res., 67, 10309-10316.
18. West, D.C. et al. (2005) Interactions of multiple heparin binding growth factors with neuropilin-1 and potentiation of the activity of fibroblast growth factor-2. J. Biol. Chem., 280, 13457-13464.
19. Dhar, K. et al. (2010) Tumor cell-derived PDGF-B potentiates mouse mesenchymal stem cells-pericytes transition and recruitment through an interaction with Nrp-1. Mol. Cancer., 9, 209.
20. Fukasawa, M. et al. (2007) Neuropilin-1 interacts with integrin beta1 and modulates pancreatic cancer cell growth, survival and invasion. Cancer Biol. Ther., 6, 1173-1180.
21. Glinka, Y. et al. (2008) Neuropilin-1 is a receptor for transforming growth factor beta-1, activates its latent form, and promotes regulatory T cell activity. J. Leukoc. Biol., 84, 302-310.
22. Prud'homme, G.J. (2007) Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab. Invest., 87, 1077-1091.
23. Mourskaia, A.A. et al. (2007) Targeting aberrant TGF-beta signaling in pre-clinical models of cancer. Anticancer Agents Med. Chem., 7, 504-514.
24. Padua, D. et al. (2009) Roles of TGFbeta inmetastasis. Cell Res., 19, 89-102.
25. Tan, A.R. et al. (2009) Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Res. Treat., 115, 453-495.
26. Chakrabarti, R. et al. (2009) Tranilast inhibits the growth and metastasis of mammary carcinoma. Anticancer Drugs, 20, 334-345.
27. Kang, J.S. et al. (2009) New regulatory mechanisms of TGF-beta receptor function. Trends Cell Biol., 19, 385-394.
28. Gordon, K.J. et al. (2008) Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim. Biophys. Acta., 1782, 197-228.
29. Mythreye, K. et al. (2009) Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion. Cell Signal., 21, 1548-1558.
30. Sheppard, D. (2005) Integrin-mediated activation of latent transforming growth factor beta. Cancer Metastasis Rev., 24, 395-402.
31. Murphy-Ullrich, J.E. et al. (2000) Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev., 11, 59-69.
32. Neufeld, G. et al. (2008) The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat. Rev. Cancer., 8, 632-645.
33. Soker, S. et al. (1996) Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J. Biol. Chem., 271, 5761-5767.
34. Timoshenko, A.V. et al. (2007) Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells. Br. J. Cancer., 97, 1090-1098.
35. Finger, E.C. et al. (2008) Endocytosis of the type III transforming growth factor-beta (TGF-beta) receptor through the clathrin-independent/lipid raft pathway regulates TGF-beta signaling and receptor down-regulation. J. Biol. Chem., 283, 34808-34818.
36. Bolte, S. et al. (2006) A guided tour into subcellular colocalization analysis in light microscopy. J. Microsc., 224, 213-232.
37. Groppe, J. et al. (2008) Cooperative assembly of TGF-beta superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding. Mol. Cell., 29, 157-168.
38. Massagué, J. (2008) A very private TGF-beta receptor embrace. Mol. Cell., 29, 149-150.
39. Hong, T.M. et al. (2007) Targeting neuropilin 1 as an antitumor strategy in lung cancer. Clin. Cancer Res., 13, 4759-4768.
40. Cao, Y. et al. (2010) Neuropolin-1 mediates divergent R-Smad signaling and the myofibroblast phenotype. J. Biol. Chem, 285, 31840-31848.
41. Margadant, C. et al. (2010) Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep., 11, 97-105.
42. Wipff, P.J. et al. (2008) Integrins and the activation of latent transforming growth factor beta1-an intimate relationship. Eur. J. Cell Biol., 87, 601-615.
43. Probst-Kepper, M. et al. (2009) GARP: a key receptor controlling FOXP3 in human regulatory T cells. J. Cell. Mol. Med., 13, 3343-3357.
44. Tran, D.Q. et al. (2009) GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells. Proc. Natl Acad. Sci. USA, 106, 13445-13450.
45. Wang, R. et al. (2009) Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells. Proc. Natl Acad. Sci. USA, 106, 13439-13444.
46. Stockis, J. et al. (2009) Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg. Eur. J. Immunol., 39, 3315-3322.
47. Teesalu, T. et al. (2009) C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc. Natl Acad. Sci. USA, 106, 16157-16162.
48. Sugahara, K.N. et al. (2009) Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell, 16, 510-520.
49. Sugahara, K.N. et al. (2010) Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science, 328, 1031-1035.
50. Di Guglielmo, G.M. et al. (2003) Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat. Cell Biol., 5, 410-421.
51. Penheiter, S.G. et al. (2010) Type II TGF-beta receptor recycling is dependent upon the clathrin adaptor protein Dab2. Mol. Biol. Cell, 21, 4009-4019.
52. Salikhova, A. et al. (2008) Vascular endothelial growth factor and semaphorin induce neuropilin-1 endocytosis via separate pathways. Circ. Res., 10, e71-e79.
53. Hasson, T. (2003) Myosin VI: two distinct roles in endocytosis. J. Cell Sci., 116, 3453-3461.